Literature DB >> 11138620

Peptide generation in the major histocompatibility complex class I antigen processing and presentation pathway.

M J Androlewicz1.   

Abstract

The bulk of antigens that are presented by major histocompatibility complex (MHC) class I molecules are processed in the cytosol. Therefore, the cellular protein degradation machinery is thought to play a major role in antigen processing. For example, there is clear evidence that the ubiquitin-proteasome pathway, the major proteolytic pathway in the cytosol, plays a role in the processing of class I-associated antigens. In addition, peptide chaperones must exist to properly target peptides to the transporter associated with antigen processing. Here, the author reviews some of the more important advances over the past year that further define the pathways of antigen breakdown in the cytosol. This includes a look at the distinctive roles of proteasomes versus immunoproteasomes, the isolation of peptide processing intermediates in the cytosol, and the role of defective ribosomal products. These findings highlight the importance of understanding basic cellular protein degradation pathways in antigen processing.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11138620     DOI: 10.1097/00062752-200101000-00003

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  2 in total

1.  Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses.

Authors:  Roberta Schiavo; Dolgor Baatar; Purevdorj Olkhanud; Fred E Indig; Nicholas Restifo; Dennis Taub; Arya Biragyn
Journal:  Blood       Date:  2006-03-02       Impact factor: 22.113

2.  Sequence evolution of putative cytotoxic T cell epitopes in NS3 region of hepatitis C virus.

Authors:  Hua-Zhang Guo; Ying Yin; Wen-Liang Wang; Chuan-Shan Zhang; Tao Wang; Zhe Wang; Jing Zhang; Hong Cheng; Hai-Tao Wang
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.